Sana Biotechnology (NASDAQ:SANA) Rating Increased to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Sana Biotechnology (NASDAQ:SANA) from a strong sell rating to a sell rating in a research note published on Saturday morning.

Other equities research analysts have also issued research reports about the company. HC Wainwright cut their target price on Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating on the stock in a research report on Wednesday, March 4th. Weiss Ratings lowered Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. Morgan Stanley restated an “overweight” rating and set a $12.00 price target on shares of Sana Biotechnology in a report on Friday, March 13th. Zacks Research downgraded shares of Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 3rd. Finally, Wedbush lifted their price objective on shares of Sana Biotechnology from $6.00 to $7.00 and gave the company an “outperform” rating in a research note on Tuesday, April 14th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.20.

Sana Biotechnology Stock Up 0.3%

SANA stock opened at $3.51 on Friday. The firm has a market cap of $947.66 million, a price-to-earnings ratio of -3.62 and a beta of 2.17. Sana Biotechnology has a 12-month low of $1.60 and a 12-month high of $6.55. The company’s fifty day simple moving average is $3.36 and its 200 day simple moving average is $4.04.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03). Research analysts expect that Sana Biotechnology will post -0.59 earnings per share for the current year.

Hedge Funds Weigh In On Sana Biotechnology

Large investors have recently modified their holdings of the company. Baillie Gifford & Co. increased its stake in Sana Biotechnology by 13.6% during the 3rd quarter. Baillie Gifford & Co. now owns 11,436,503 shares of the company’s stock valued at $40,600,000 after purchasing an additional 1,371,775 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Sana Biotechnology by 19.9% in the third quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company’s stock valued at $32,408,000 after buying an additional 1,517,474 shares in the last quarter. State Street Corp grew its holdings in shares of Sana Biotechnology by 20.6% during the fourth quarter. State Street Corp now owns 8,054,841 shares of the company’s stock valued at $32,783,000 after buying an additional 1,374,300 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Sana Biotechnology by 20.3% during the fourth quarter. Geode Capital Management LLC now owns 4,118,138 shares of the company’s stock valued at $16,763,000 after buying an additional 694,606 shares during the last quarter. Finally, Integral Health Asset Management LLC increased its position in shares of Sana Biotechnology by 50.0% during the fourth quarter. Integral Health Asset Management LLC now owns 3,000,000 shares of the company’s stock worth $12,210,000 after acquiring an additional 1,000,000 shares in the last quarter. 88.23% of the stock is currently owned by institutional investors.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.